ArticleDigestive diseases and sciences2016
Direct Costs in Patients with Celiac Disease in the USA: A Retrospective Claims Analysis.
Article in Digestive diseases and sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Literature Review of the Economic Burden of Celiac Disease.PharmacoEconomics · 2019Pooled it
- Latiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients With Celiac Disease Exposed to a Gluten Challenge.Gastroenterology · 2022Trial
- Enhancing food insecurity screening in pediatric celiac disease using a quality improvement framework.Journal of pediatric gastroenterology and nutrition · 2025Article
- Burden of coeliac disease in Germany: real-world insights from a large retrospective health insurance claims database analysis.Therapeutic advances in gastroenterology · 2025Article
- Article
- Patterns of practice in the diagnosis, dietary counselling and follow-up of patients with celiac disease- A patient-based survey.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023Article
- The global burden of coeliac disease: opportunities and challenges.Nature reviews. Gastroenterology & hepatology · 2022Review
- Healthcare Resource Utilization and Costs in Celiac Disease: A US Claims Analysis.The American journal of gastroenterology · 2020Article
- Celiac Disease: Against the Grain in Gastroenterology.Journal of the Canadian Association of Gastroenterology · 2019Article
- Latiglutenase Treatment for Celiac Disease: Symptom and Quality of Life Improvement for Seropositive Patients on a Gluten-Free Diet.GastroHep · 2019Article
- UEG Week 2019 Poster Presentations.United European gastroenterology journal · 2019Article
- Gluten Intake and Risk of Celiac Disease: Long-Term Follow-up of an At-Risk Birth Cohort.The American journal of gastroenterology · 2019Article
- Economic burden made celiac disease an expensive and challenging condition for Iranian patients.Gastroenterology and hepatology from bed to bench · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCeliac disease (CeD) is an autoimmune disease triggered by gluten ingestion.
aimWe assessed total direct costs burden associated with CeD in patients with CeD versus patients without CeD using administrative claims data.
methodsPatients with CeD (cases) with ≥1 occurrences of CeD diagnosis were selected at a randomly chosen date (index date) from the OptumHealth Reporting and Insights database from 01/01/1998 through 03/31/2013. Cases were continuously enrolled throughout baseline (1 year before index date) and study (1 year after index date) periods. Cases were categorized as full remission and partial remission and matched 1:1 based on age, sex, region, index date, company, and employment status. Total all-cause and CeD-related costs were calculated.
resultsA total of 12,187 cases were matched with an equal number of controls. Mean total all-cause costs were $12,217 in cases versus $4935 in controls (P < 0.0001). In full remission (N = 10,181 [83.5 %]) and partial remission (N = 2006 [16.5 %]) cases, mean total all-cause direct costs (cases versus controls) were $11,038 versus $4962 and $18,206 versus $4796, respectively. All-cause medical costs ($9839 for all cases, $8723 for full remission cases, $15,499 for partial remission cases) accounted for the majority of all-cause total costs and included outpatient costs ($6675; $6456; and $7785, respectively) and hospitalizations ($2776; $1963; and $6906, respectively). CeD-related medical costs were 13 and 27 % of all-cause medical costs for all cases and partial remission cases, respectively.
conclusionsPatients with CeD and partial remission of CeD incurred significantly higher (2.5 and 3.8 times) total all-cause costs compared with matched controls.
Indexed as
Identifiers
27417565What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.